SAKAR HEALTHCARE LIMITED
SAKAR · General/Diversified · NSE
₹615
Current Market Price
Fair Value (DCF)
₹142
Margin of Safety
-76.9%
Updated 1d ago
YieldIQ Score
43/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
24%
ROE
—
Debt/Equity
0.28
WACC
11.1%
Market Cap
₹1,350 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
8.4%
Return on capital employed
EV / EBITDA
25.2×
Enterprise multiple
Debt / EBITDA
1.5×
Leverage vs earnings
Interest Coverage
3.7×
EBIT covers interest
Current Ratio
1.40×
Short-term liquidity
Asset Turnover
0.43×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹615.25
Bear case
₹78.52
MoS -683.6%
Base case
₹141.84
MoS -333.8%
Bull case
₹187.14
MoS -228.8%
Ratio Trends
SAKAR · last 7 annual periods
ROE
6.1%
ROCE
13.5%
Operating Margin
—
Debt / Equity
0.30×
PE
112.3×
EV / EBITDA
12.1×
Historical Financials
SAKAR · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹94.7 Cr | ₹128 Cr | ₹40.7 Cr | ₹43.1 Cr | ₹178 Cr | +17.0% |
| EBITDA | — | ₹31.3 Cr | ₹37.3 Cr | ₹40.7 Cr | ₹50.3 Cr | +12.6% |
| EBIT | ₹15.7 Cr | ₹21.8 Cr | ₹6.0 Cr | ₹6.9 Cr | — | -18.7% |
| PAT | ₹10.7 Cr | ₹15.2 Cr | ₹3.9 Cr | ₹3.1 Cr | ₹17.5 Cr | +13.1% |
| EPS (diluted) | ₹6.87 | ₹8.73 | ₹2.04 | ₹1.45 | — | -32.2% |
| CFO | ₹14.6 Cr | ₹35.7 Cr | ₹33.3 Cr | ₹24.5 Cr | ₹34.0 Cr | +23.6% |
| CapEx | — | — | — | — | ₹-32.3 Cr | — |
| FCF | — | — | — | — | ₹1.7 Cr | +0.0% |
| Total Assets | — | ₹268 Cr | ₹336 Cr | ₹389 Cr | ₹415 Cr | +11.6% |
| Total Debt | — | — | ₹13.0 Cr | ₹13.9 Cr | ₹86.4 Cr | +60.5% |
| Shareholders' Equity | — | — | ₹173 Cr | ₹262 Cr | ₹285 Cr | +13.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SAKAR vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| JAGSNPHARM JAGSONPAL PHARMACEUTICALS | -6.1% | 61 | Fairly valued | 23.1% | — |
| SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
| BETA BETA | — | — | Pending | 21.5% | — |
| VENUSREM VENUSREM | — | — | Pending | 8.1% | — |
| BAJAJHCARE BAJAJHCARE | — | — | Pending | 8.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SAKAR in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SAKAR →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SAKAR →
Compare
Head-to-head with peers
Compare SAKAR side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SAKARNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.